Navigation Links
Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer
Date:5/21/2013

BURLINGTON, Mass., May 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the effect of an emerging agent on key efficacy endpoints, including overall survival and time to disease progression, has the most influence over surveyed U.S. and European oncologists' prescribing decisions for advanced/metastatic hormone-receptor (HR-) positive, HER2-negative breast cancer. The two novel emerging therapies palbociclib (Pfizer's PD-0332991) and buparlisib (Novartis's BKM-120), both in combination with currently available hormonal therapies, are set to offer efficacy advantages over currently available agents used to treat this patient population.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The Decision Base 2013 report entitled Breast Cancer (Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic): What Attributes will Distinguish Emerging Therapies in the Eyes of Oncologists and Payers?, finds that surveyed U.S. oncologists would prescribe palbociclib to 50 percent of their first-line advanced/metastatic HR-positive, HER2-negative breast cancer patients.

The report also finds that surveyed managed care organization (MCO) pharmacy directors are particularly receptive to novel therapies that offer an improvement in overall response rate (ORR) in this patient population. However, while several emerging therapies hold promise, Decision Resources does not expect any will match the clinical improvement in ORR over current therapies that surveyed U.S. payers indicated would be necessary for widespread inclusion on MCO formularies.

"This population represents a large and therefore potentially lucrative market segment for drug developers," said Decision Resources Principal Analyst Amy Duval . "The majority of hormonal therapies used to treat patients in this population are generic, and market dynamics had been stagnating until last year's approval of everolimus (Novartis's Afinitor) in this population. Uptake of everolimus and the development of promising late-stage clinical prospects such as palbociclib and buparlisib are set to reinvigorate this market segment."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

 


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Next Generation Pharmaceutical Manufacturing Summit Pushes the Envelope of Thought-Leadership at its September Summit in London
2. Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe
3. Ludlow Research Issues Opinion on PMBS Based on Low Market Cap Valuation
4. For Osteoporosis and Osteopenia, Clinical Data and Thought Leaders Opinions Indicate that AMG-785/CDP-7851 and Odanacatib Have Advantages Over Alendronate
5. In Pretreated Advanced Renal Cell Carcinoma, Thought Leaders Opinions and Clinical Data Indicate that Tivopath Has Efficacy and Tolerability Advantages Over Currently Used Therapies
6. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
7. Active Lifes BioDent Reference Point Indenter Validated in Study Published by Osteoporosis Medical Opinion Leaders
8. Albireo Receives Positive Opinion for Orphan Drug Designation for A4250 for Severe Liver Diseases
9. Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions
10. Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR
11. A*STAR and Cytos Bring Singapores First Influenza Vaccine to Clinical Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Ischemic Stroke Market ... to their offering.       (Logo: ... Global Acute Ischemic Stroke Market and Competitive ... Acute Ischemic Stroke pipeline products, Acute Ischemic ...
(Date:5/3/2016)... May 3, 2016 BioNovus Innovations LLC ... for Advancing Medical Innovation (IAMI) today announced a ... diagnostics and medical devices. An agreement ... rights to license, develop and commercialize medical innovations ... "This partnership represents a significant advance in ...
(Date:5/3/2016)... 3, 2016   BIOTRONIK , a leader ... Food and Drug Administration (FDA) approval of Iperia ... heart failure patients with access to diagnostic magnetic ... remote monitoring with daily automatic transmission and closed ... in response to physiological demands. ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... ... A new collaboration will give more researchers access to the largest and oldest ... SAS will provide researchers worldwide with data management and analytics tools to explore 45 ... The DCRI and SAS share the goal of greater transparency and openness in research ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... April 2016. SS&A teamed up with one of the top website design companies ... portal contains informative legal articles related to the law firm's main practice areas. ...
(Date:5/4/2016)... ... May 04, 2016 , ... Francesca Loparco, Co-Founder of Queen City Dream Cars, ... same-day LASIK procedure at Christenbury Eye Center. The entrepreneur struggled with her ... surgery the same day as her in-office consultation and eye exam. Francesca’s eyesight was ...
(Date:5/4/2016)... ... May 04, 2016 , ... Advanced Spine & Sport ... restore its patients’ health, is hosting a free seminar on stem cell injections. The ... at Advanced Spine & Sport, 4601 Telephone Road, Suite 110, Ventura, CA. There are ...
(Date:5/4/2016)... ... 2016 , ... Mediware Information Systems, Inc . has ... helps blood and marrow transplant (BMT) programs meet compliance and accreditation standards while ... to enhance core application features. These enhancements are designed to help BMT programs ...
Breaking Medicine News(10 mins):